Search results
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular...
Morningstar· 6 days ago"RINVOQ has been an important addition to the treatment landscape for various rheumatic diseases, helping adult patients achieve meaningful disease control," said Roopal Thakkar, M.D., senior ...
AbbVie’s RINVOQ now indicated for paediatric arthritis in US
Pharmaceutical Technology via Yahoo Finance· 5 days agoIn May 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use...
FDA Extends Upadacitinib Indications to Kids With Arthritis
Medscape· 6 days agoThe JAK inhibitor's safety profile for patients as young as 2 years was similar to known to the...
Rhode Islanders face massive barriers to health care | Opinion
The Providence Journal via Yahoo News· 4 days agoThis monumental cost makes it extremely difficult for me to afford my necessary treatments and medicine. There is no alternative or generic medicine for ...
Simponi and Simponi Aria cost: Reducing long-term costs and more
Medical News Today· 7 days agoSimponi and Simponi Aria both contain the active ingredient golimumab. A biosimilar medication is a...
AbbVie Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU - AbbVie (NYSE:ABBV), ALX Oncology...
Benzinga· 6 days agoPlease note that Skyrizi is already approved in the United States and EU for treating plaque...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 3 days agoSkyrizi is already approved in the United States and the EU for treating plaque psoriasis, psoriatic...
Health Matters: Lymphedema Act of 2024
The Escanaba Daily Press· 1 hour agoThe Lymphedema Act was passed, providing for clearly defined benefits in the treatment of this condition, with many options now available for effective care. At this point in the conversation ...
Inebilizumab 'MITIGATES' Flare Risk in IgG4-Related Disease
Medscape· 3 days agoInebilizumab-cdon reduced the risk for flares by 87% in patients with IgG4-RD, the MITIGATE study showed.
How Can Cardiovascular Risk Be Reduced in Kidney Dialysis?
Medscape· 5 days agoNew data on clazakizumab, a monoclonal antibody targeting interleukin-6 (IL-6), and home...